Rate My Professor Jo Robson

Robson leads the international development of the AAV-PRO for ANCA-associated vasculitis, translated into 14 languages and embedded in clinical registries and trials; the GCA-PRO for giant cell arteritis; and the Steroid-PRO for glucocorticoid impact via the OMERACT Glucocorticoid Impact Working Group. She chairs the steering committee of the American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis (DCVAS) study, serves on the UK and Ireland Vasculitis Service (UKIVAS) registry steering committee, and is a member of the European Vasculitis Society (EUVAS). With over 90 publications garnering more than 2,200 citations, notable works include 'Introduction, epidemiology and classification of vasculitis' (2018, Best Practice & Research Clinical Rheumatology), 'Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure' (2017, Rheumatology), 'Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire' (2018), 'Quality standards for the care of people with giant cell arteritis in secondary care' (2023, Rheumatology), and 'Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England' (2023). Her contributions significantly influence clinical standards and research in rheumatology.